Blueshift Asset Management’s Royalty Pharma RPRX Stock Holding History

Blueshift Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,609	Closed	-$225K	–	591
2022 Q3	$225K	Buy	+5,609	New	+$240K	0.05%	481
2021 Q4	–	Sell	-12,534	Closed	-$453K	–	1173
2021 Q3	$453K	Sell	12,534 -32,178	-72%	-$1.25M	0.03%	665
2021 Q2	$1.83M	Buy	44,712 +39,084	+694%	+$1.66M	0.1%	233
2021 Q1	$245K	Buy	+5,628	New	+$267K	0.03%	707

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blueshift Asset Management's RPRX Position: Q4 2022 in Review

Blueshift Asset Management sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 5,609 shares — an estimated $225K sold.

Blueshift Asset Management first reported a position in RPRX in Q1 2021 and held it in 4 quarters. The position peaked at $1.83M in Q2 2021. 334 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

Blueshift Asset Management reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
Blueshift Asset Management sold 5,609 Royalty Pharma shares in Q4 2022, an estimated $225K.
Blueshift Asset Management first reported a position in Royalty Pharma in Q1 2021 and held it in 4 quarters.
Blueshift Asset Management's Royalty Pharma position peaked at $1.83M in Q2 2021.
334 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Blueshift Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.